Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fusion AntibodiesLSE:FAB 17 3-1 Month Momentum % is -17.31% as of Aug. 27, 2026. GuruFocus rates LSE:FAB with a GF Score™ of 17/100 and a GF Value™ of £0.04 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,384 Biotechnology companies, Fusion Antibodies ranks worse than 65.46% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-27), Fusion Antibodies's 3-1 Month Momentum % is -17.31%.
The industry rank for Fusion Antibodies's 3-1 Month Momentum % or its related term are showing as below:
LSE:FAB's 3-1 Month Momentum % is ranked worse than 65.46% of 1384
companies
in the Biotechnology industry
Industry Median: -9.34
vs LSE:FAB: -17.31
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Fusion Antibodies 3-1 Month Momentum % Related Terms
LSE:FAB vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Fusion Antibodies's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fusion Antibodies 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fusion Antibodies's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Fusion Antibodies's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fusion Antibodies (LSE:FAB) has a 3-1 Month Momentum % of -17.31% as of Aug. 27, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Fusion Antibodies and its competitors. According to the industry distribution chart, Fusion Antibodies ranks #906 out of 1384 companies in the Biotechnology industry, placing it in the top 65.5%.
Is Fusion Antibodies' 3-1 Month Momentum % too high?
Fusion Antibodies' current 3-1 Month Momentum % is -17.31%. Based on the distribution chart, Fusion Antibodies ranks #906 out of 1384 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Fusion Antibodies has a GF Score™ of 17/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fusion Antibodies' 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fusion Antibodies ranks #906 out of 1384 companies for 3-1 Month Momentum %. This places Fusion Antibodies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Fusion Antibodies and its competitors. Fusion Antibodies's current 3-1 Month Momentum % is -17.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fusion Antibodies stock overvalued right now?
Based on GuruFocus' analysis, Fusion Antibodies (LSE:FAB) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.04, compared to a current price of £0.11 — trading 181.3% above its estimated fair value. The current 3-1 Month Momentum % is -17.31%. Fusion Antibodies' overall GF Score™ is 17/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Fusion Antibodies (LSE:FAB), the current 3-1 Month Momentum % is -17.31% as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fusion Antibodies (LSE:FAB) Overvalued in 2026?
Based on GuruFocus' analysis, Fusion Antibodies stock appears to be overvalued.
The current stock price of £0.11 is trading 181.3% above its estimated GF Value™ of £0.04.
GuruFocus considers Fusion Antibodies to be Significantly Overvalued.
Key valuation signals for LSE:FAB:
3-1 Month Momentum %: -17.31%
GF Value™: £0.04 vs. price of £0.11 (181.3% above fair value)
No single metric tells the full story. See the LSE:FAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.
17GF Score
Get the complete analysis for LSE:FAB
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:FAB has been successfully added to your 
